This website uses cookies
Read our Privacy policy and Terms of use for more information.
CV
+4

Aug 18, 2026
•
14 min read
Remnant cholesterol costs nothing to calculate and predicts events when LDL no longer does. Its first real drug just proved it can prevent pancreatitis, and then failed to move plaque.

CV
+4

Aug 15, 2026
•
9 min read
Lp(a) is the most common inherited cardiovascular risk factor in medicine — and the first outcomes trial that could give us a drug for it has gone quiet.

CV
+1

Jun 13, 2026
•
7 min read
A new natural-history study watched atherosclerosis grow in untreated, low-risk adults over five years — and quietly made the strongest case I’ve seen in years for treating LDL early and aggressively.

CV
+2

Jun 9, 2026
•
10 min read
Lp(a) drives heart attacks, strokes, and aortic stenosis in one in five people. Statins don’t touch it. Diet doesn’t move it. After six decades of therapeutic silence, 2026 is the year the verdict finally arrives — and a single gene edit may make the problem history.

CV
+3

Apr 15, 2026
•
16 min read
Muscle damage. Memory loss. Cancer. Diabetes. Four fears, one physician, and what the evidence actually shows.

CV
+3

Apr 11, 2026
•
12 min read
The receptor story that explains 40 years of cardiovascular outcomes data — and why the pleiotropic hypothesis was never the whole story.

SUBSCRIBE TO MY NEWSLETTER